Obesity is associated with impaired endothelial function, and this may lead to increased cardiovascular risk. To gain insight into the beneficial effects of diet induced weight loss on endothelial function, endothelium dependent, flow-mediated dilation (FMD) of the brachial artery and several metabolic and inflammatory markers were assessed in 40 obese women at baseline, after the 1st week and after 5 months on a low-calorie diet and in twenty lean women. At entry, the obese women had a lower FMD than the lean women. Improvements in obesity-related endothelial dysfunction began in the 1st week of dieting and continued during the following months of this simple non-pharmacological lifestyle modification to reach normalisation of endothelial function.
COBISS.SI-ID: 3853887
Peripheral arterial disease (PAD) is associated with frequent cardiovascular ischemic events. We followed the survival of 811 PAD patients and and 778 control subjects and tested whether PAD remains an adverse prognostic indicator in spite of treatment according to the current European guidelines on cardiovascular disease prevention. Patients with PAD had a borderline higher risk of all-cause death and a significantly higher risk of major and minor non-fatal cardiovascular events compared to control subjects. However, treatment according to the European guidelines on cardiovascular disease prevention resulted in encouragingly low absolute mortality and morbidity.
COBISS.SI-ID: 29415385
Activation of haemostasis (hypercoagulability) is ideally detected prior to the appearance of thrombotic phenomena. Laboratory recognition of hypercoagulability is, however, a very demanding task due to the complexity of the haemostatic system. It can be detected by global tests (such as activated partial thromboplastin time, thrombelastography, thrombin generation assays or overall haemostasis potential) that provide an overview of the entire haemostatic system, including enzymes, cofactors and inhibitors. Another approach to detecting hypercoagulability is to measure specific peptides, enzymes, enzyme-inhibitor complexes (such as fibrinopeptide 1+2, thrombin-antithrombin complex, D-dimer) that are liberated with activation of the coagulation and fibrinolysis systems in vivo.. The most recent method to assess hypercoagulability is to detect molecules that are released from activated endothelial and blood cells in response to injury of the vessel wall (markers of endothelial and platelet activation).
COBISS.SI-ID: vpis v por